Roivant Sciences (ROIV) Stock Surges 20% as Three Street Firms Initiate Coverage With Positive Ratings

Go back to Roivant Sciences (ROIV) Stock Surges 20% as Three Street Firms Initiate Coverage With Positive Ratings

Jefferies Starts Roivant Sciences (ROIV) at Buy

October 26, 2021 7:38 AM EDT

Jefferies analyst Dennis Ding initiates coverage on Roivant Sciences (NASDAQ: ROIV) with a Buy rating and a price target of $10.00.

The analyst commented, "ROIV is a diversified healthcare company employing a novel hub-and-spoke model, which enables its 10+ subsidiaries (Vants) substantial flexibility in maximizing... More

Truist Securities Starts Roivant Sciences (ROIV) at Buy

October 26, 2021 6:09 AM EDT

Truist Securities analyst Robyn Karnauskas initiates coverage on Roivant Sciences (NASDAQ: ROIV) with a Buy rating and a price target of $15.00.

The analyst commented, "Roivants novel business model underappreciated by investors, in our view; with their evolving AI technology platform and... More

Cowen Starts Roivant Sciences (ROIV) at Outperform

October 26, 2021 5:38 AM EDT

Cowen analyst Yaron Werber initiates coverage on Roivant Sciences (NASDAQ: ROIV) with an Outperform rating.

The analyst commented, "Roivant aims to revolutionize drug development by integrating multiple subsidiaries discovery platforms with others manufacturing/clinical resources. Dermavants tapinarof is highly promising based on consultant... More